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Objectives The aim of this study was to assess the effects of serelaxin on short-term changes in markers of organ damage
and congestion and relate them to 180-day mortality in patients with acute heart failure.
Background Hospitalization for acute heart failure is associated with high post-discharge mortality, and this may be related
to organ damage.
Methods The Pre-RELAX-AHF (Relaxin in Acute Heart Failure) phase II study and RELAX-AHF phase III study were international,
multicenter, double-blind, placebo-controlled trials in which patients hospitalized for acute heart failure were random-
ized within 16 h to intravenous placebo or serelaxin. Each patient was followed daily to day 5 or discharge and at
days 5, 14, and 60 after enrollment. Vital status was assessed through 180 days. In RELAX-AHF, laboratory evalua-
tions were performed daily to day 5 and at day 14. Plasma levels of biomarkers were measured at baseline and days
2, 5, and 14. All-cause mortality was assessed as a safety endpoint in both studies.
Results Serelaxin reduced 180-day mortality, with similar effects in the phase II and phase III studies (combined studies:
N  1,395; hazard ratio: 0.62; 95% confidence interval: 0.43 to 0.88; p  0.0076). In RELAX-AHF, changes in
markers of cardiac (high-sensitivity cardiac troponin T), renal (creatinine and cystatin-C), and hepatic (aspartate
transaminase and alanine transaminase) damage and of decongestion (N-terminal pro–brain natriuretic peptide)
at day 2 and worsening heart failure during admission were associated with 180-day mortality. Serelaxin admin-
istration improved these markers, consistent with the prevention of organ damage and faster decongestion.
Conclusions Early administration of serelaxin was associated with a reduction of 180-day mortality, and this occurred with
fewer signs of organ damage and more rapid relief of congestion during the first days after admission. (J Am
Coll Cardiol 2013;61:196–206) © 2013 by the American College of Cardiology Foundation
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Januay 15, 2013:196–206 The RELAX-AHF TrialAcute heart failure (AHF) is the most common cause of
hospitalization in patients older than 65 years, with a
mortality rate reaching 30% to 40% within 1 year (1–5).
ecent studies have implicated organ damage and persistent
r recurrent congestion during the first days after admission
s contributors to this poor prognosis (3,6–8). Injury or
nd-organ dysfunction, including myocardial damage, wors-
ning renal function, and hepatic impairment, is an inde-
endent predictor of increased mortality in patients with
HF (3,9–11). Signs of unresolved congestion and its most
evere manifestation, episodes of worsening heart failure,
re also strong predictors of poor outcomes (12–14). There-
ore, it has been hypothesized that the prevention of organ
amage and relief from congestion may be associated with
ower mortality of patients with AHF (3,7,9,15).
Serelaxin is a recombinant form of human relaxin-2, a
aturally occurring peptide hormone that increases during
regnancy and mediates the maternal physiological cardio-
ascular and renal adaptations and has potential protective
ffects against organ damage (16–18). The RELAX-AHF
Relaxin in Acute Heart Failure) study examined the effects
f serelaxin in patients with AHF. In this study, serelaxin
mproved 1 of the 2 primary endpoints, dyspnea measured
sing a visual analogue scale to day 5, but did not affect the
ther primary endpoint of dyspnea relief assessed using a
ikert scale at 6, 12, and 24 h and did not reduce the rate
f cardiovascular death or heart failure readmissions to day
0 or days alive and out of the hospital to day 60 (secondary
ndpoints). All-cause 180-day mortality, a pre-specified
afety endpoint of the trial, was significantly reduced by
erelaxin administration, and these results were similar to
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report, we describe the effects of serelaxin on pre-specified
markers of cardiac, renal, and liver damage, as well as signs
and symptoms of congestion res-
olution. In a post hoc exploratory
analysis, we explored the associ-
ation of these changes with 180-
day mortality in the RELAX-
AHF trial.
Methods
Study design. Both the Pre-
RELAX-AHF phase II and the
RELAX-AHF phase III studies
were randomized, double-blind,
placebo-controlled, parallel-group,
international trials comparing the
intravenous administration of sere-
laxin for up to 48 h, started within
16 h of presentation, with placebo in patients hospitalized for
AHF with dyspnea, congestion on chest radiography, in-
creased natriuretic peptide levels, mild to moderate renal
insufficiency, and systolic blood pressure 125 mm Hg.
Background, design, and main results for both studies have
been published (19–21).
Procedures. In the RELAX-AHF phase III study, blood
samples were collected in all patients at baseline and at 24 h
(day 1); 48 h (day 2); on days 3 and 4, if in hospital; and on
days 5, 14, and 60 for standard hematology and chemistry at
a central laboratory using commercially available, validated
assays. Serum creatinine and transaminases were assessed as
variables related to renal and liver function.
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transaminase
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The RELAX-AHF Trial Januay 15, 2013:196–206Measurements of high-sensitivity cardiac troponin T
(hs-cTnT), cystatin-C, and N-terminal pro–brain natri-
uretic peptide (NT-proBNP) were pre-specified in the
protocol as biomarkers related to myocardial damage, kid-
ney injury, and decongestion, respectively. These biomark-
ers were measured in all patients at baseline and on days 2,
5, and 14 at an independent central laboratory. All samples
from the same patient were analyzed in the same batch by
laboratory personnel blinded to subject treatment and study
data. Plasma hs-cTnT was measured using the high-
sensitivity Roche Elecsys assay (lot number 167345; Roche
Diagnostics GmbH, Mannheim, Germany). The 99th-
percentile upper reference limit was 0.014 g/l, and the lowest
oncentration with a coefficient of variation 10% was 0.013
g/l. NT-proBNP plasma levels were measured using the
Roche Elecsys proBNP assay (Roche Diagnostics GmbH),
which has a reporting range of 5 to 35,000 ng/l. Cystatin-C
plasma levels were measured using the Gentian Cystatin C
Immunoassay (Beckman Coulter, Brea, California), with a
reporting range of 0.25 to 8.4 mg/l (18.7 to 629 nmol/l).
Definitions. Cutoff values to categorize plasma hs-cTnT,
cystatin-C, and NT-proBNP changes were defined on the
basis of previous studies and guidelines. Consistent with the
universal definition of myocardial infarction, hs-cTnT concen-
tration was defined a priori as elevated when its value exceeded
the 99th percentile of the upper reference limit for the assay:
0.014 g/l (22). Additional thresholds were chosen post hoc
on the basis of current published recommendations. We
defined substantial additional myocardial necrosis as a further
increase in hs-cTnT level of at least 20% (23,24).
Worsening renal function was defined as increases in
serum creatinine and plasma cystatin-C values of 0.3
mg/dl (27 mol/l) and 0.3 mg/l (22 nmol/l), respectively,
from the values measured at baseline, consistent with
previously published studies (9,25,26). A decrease in NT-
proBNP of 30% relative to baseline at day 2 was defined
as clinically meaningful, according to previous studies
(27,28). Evidence of hepatic damage was taken as 20% or
greater increases from baseline to day 2 in aspartate
transaminase (AST) and alanine transaminase (ALT).
Worsening heart failure was determined by the investi-
gator using a scripted 1-page form and, similar to previous
studies (12–14,29,30), and was defined as worsening signs
and/or symptoms of heart failure requiring reinstitution or
intensification of intravenous or mechanical therapy for
heart failure.
Statistical analysis. Analyses were conducted on the
intention-to-treat principle, with patients allocated accord-
ing to randomized treatment. Analyses of plasma chemistry
changes included patients treated with the study drug who
had both baseline values and at least 1 follow-up value.
Biomarkers (hs-cTnT, cystatin-C, and NT-proBNP) were
analyzed in patients who had both baseline values and at
least 1 follow-up value. Biomarker levels below the lower
limit of quantification (or reporting range) were imputed as
half the lower limit of quantification, and values above theupper limit of quantification were imputed as 1.5 times the
upper limit of quantification. Values were log transformed
for analysis, and treatment groups were compared using
repeated-measures analysis of variance with adjustment for
baseline values. Kaplan-Meier estimates of the cumulative
risk for mortality through 180 days are presented, and
groups were compared using log-rank tests. Unadjusted and
adjusted hazard ratios (HRs) and 95% confidence intervals
(CIs) were estimated from Cox regression models. A
multivariable model for predicting 180-day all-cause mor-
tality was constructed from baseline characteristics, includ-
ing clinical and laboratory variables and biomarkers in the
patients assigned to placebo, using backward selection, with
the criterion for retaining in the model at p  0.10. The
association of serelaxin with 180-day all-cause mortality was
then adjusted for the covariates included in this multivariate
model in the full dataset. A post hoc analysis was performed
in which the HR for 180-day all-cause mortality comparing
serelaxin with placebo combined across Pre-RELAX-AHF
and RELAX-AHF was estimated using Cox regression
with stratification by study. Stratified Kaplan-Meier esti-
mates were obtained using Mantel-Haenszel weighting of
the results of the 2 studies, and treatments were compared
using a stratified log-rank test. The number needed to treat
to prevent 1 death by 180 days was estimated as the inverse
of the absolute risk reduction (31).
Role of the funding source. The study was designed by the
members of the executive committee, which included 2 Cor-
thera clinical scientists, and was part of a phase II/III trial
design (20). Data collection and analysis were performed by
contract research organizations. The study databases were held
by the sponsor. The authors had access to tables and listings
supplied by the sponsor but did not have independent access to
the study databases. The executive committee had full access to
the final tables and figures. The authors not employed by the
sponsor had ultimate editorial authority, with no interference
by the sponsor on their final interpretation.
Results
The RELAX-AHF study examined the effect of serelaxin on
dyspnea reduction and 60-day outcomes (21). One thousand
one hundred sixty-one patients (placebo, n  580; serelaxin,
n 581) in Eastern Europe (n 562), Western Europe (n
204), North America (n 114), South America (n 71), and
Israel (n  210) were enrolled in RELAX-AHF. One thou-
sand one hundred thirty-eight patients (98%) received ran-
domized study medication. Study drug infusion was main-
tained for the full 48 h in 929 of these patients (82%) (484 on
placebo and 445 on serelaxin). Patients’ characteristics are
summarized elsewhere (21). A total of 1,126 randomized
patients (97%) had both baseline and at least 1 follow-up
standard chemistry result, and 1,102 (95%) had baseline and
follow-up biomarker values.
The main results of the study have been published elsewhere
(21). In short, serelaxin significantly reduced dyspnea, as
cale ran
nce inte
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Januay 15, 2013:196–206 The RELAX-AHF Trialmeasured by change from baseline on a 100-point visual
analogue scale over 5 days, but did not affect dyspnea reduction
as measured using a 7-point, Likert scale over the first 24 h
(primary end-points). Serelaxin administration did not affect
60-day readmissions or death, largely because of the lack of an
effect on readmissions (the secondary composite end-points).
Serelaxin administration was associated with other beneficial
effects on congestion, length of stay in the intensive care unit,
and length of initial hospital stay as well as a reduction of
180-day all-cause mortality (21).
Effects of serelaxin on 180-day all-cause mortality. In
RELAX-AHF, serelaxin significantly reduced 180-day all-
cause mortality, and this result remained significant after
adjustment for baseline characteristics found to be associ-
ated with 180-day all-cause mortality by multivariate anal-
ysis in the placebo group (HR: 0.64; 95% CI: 0.43 to 0.95)
(Table 1). These results are consistent with those of the phase
II Pre-RELAX-AHF study (Fig. 1) (19). In Pre-RELAX-
AHF, the HR for all serelaxin dose groups combined versus
placebo was 0.53 (95% CI: 0.22 to 1.30; p  0.16). A
combined analysis of these 2 trials confirmed the reduction in
all-cause mortality at 180 days by serelaxin, with a combined
HR of 0.62 (95% CI: 0.43 to 0.88; p 0.0076), with a number
needed to treat to save one life of 24. Survival curves in all
analyses began to separate after day 5 onward through day 180.
Effects of serelaxin on organ damage. The risk for dying
associated with incremental changes in hs-cTnT, NT-
proBNP, cystatin-C, and creatinine from baseline to day 2,
adjusted for baseline levels, in RELAX-AHF is shown in
Table 2. Risks associated with changes in these biomarkers
exceeding the clinically significant cutoffs defined a priori
are given in Table 3. The effects of serelaxin on changes in
biomarkers and standard markers of renal and liver function
Multivariable-Adjusted Association of Serelaxin180-D y Mortality in the Relaxin in Acute HeartTable 1 Mul ivariable-Adjusted Associatio180-Day Mortality in the Relaxin in
Covariate*
HR for Con
is for a
Serelaxin treatment
Age (yrs) 1 yr
CHF 1 month previously
Stroke or other cerebrovascular event
Respiratory rate (breaths/min) 1 b
Systolic BP (mm Hg) 10
Edema‡ 2/3
Orthopnea‡ 2/3
Lymphocytes (%) 5%
Sodium (mmol/l)† 3 m
Creatinine (mg/dl) 1 m
Log2 troponin T Dou
*Covariates considered but not included in the final model weremale s
blood pressure, chronic obstructive pulmonary disease, diabetes, ische
smoking, ejection fraction, baseline dyspnea visual analogue scale sco
blood urea nitrogen, hemoglobin, rales, jugular venous pressure, N-te
equivalent to milliequivalents per liter. ‡Edema was evaluated in any
after the patient rested supine for 10 to 15 min and was rated on a s
BP  blood pressure; CHF  congestive heart failure; CI  confideare shown in Table 4.MYOCARDIAL DAMAGE. At baseline, hs-cTnT plasma levels
were higher than the upper reference limit in 93% of
patients. Baseline hs-cTnT levels were associated with
180-day all-cause mortality, with an HR of 1.41 (95% CI:
1.21 to 1.64) for any doubling of hs-cTnT levels. Increases
from baseline in hs-cTnT levels at days 2, 5, and 14 were
also associated with increased 180-day all-cause mortality
(Table 2), and an increase of 20% over baseline at day 2
nearly doubled the risk (Table 3, Fig. 2A).
Baseline hs-cTnT levels were similar between the sere-
laxin and placebo groups (Table 4). Serelaxin administration
was associated with significantly lower hs-cTnT levels at
re Studyrelaxin With
e Heart Failure Study
s Variable
ase of HR 95% CI p Value
0.64 (0.43–0.95) 0.026
1.02 (1.00–1.04) 0.069
0.69 (0.44–1.06) 0.094
1.68 (1.06–2.67) 0.028
in 1.02 (0.98–1.07) 0.24
0.83 (0.73–0.95) 0.0073
1 1.49 (1.00–2.22) 0.050
1 2.68 (1.38–5.23) 0.0037
0.80 (0.69–0.93) 0.0037
0.77 (0.67–0.88) 0.0001
1.97 (1.29–3.01) 0.0016
1.41 (1.21–1.64) 0.0001
e race, enrolled in United States, bodymass index, heart rate, diastolic
rt disease, peripheral vascular disease, hyperlipidemia, hypertension,
from presentation to randomization, albumin, alanine transaminase,
ro–brain natriuretic peptide, and cystatin-C. †Millimoles per liter are
ent area on a scale ranging from 0 to 3; orthopnea was evaluated
ging from 0 to 3: 0  none, 1  1 pillow, 2  2 pillows, 3  30°.
rval; HR  hazard ratio.
S
ur
vi
va
l P
ro
b
ab
ili
ty
Pre-RELAX-AHF: Placebo
 Pre-RELAX-AHF: p=0.16
 RELAX-AHF: p=0.020
 Combined: p=0.0076
RELAX-AHF: Placebo
Combined: Placebo
Pre-RELAX-AHF: Serelaxin
RELAX-AHF: Serelaxin
Combined: Serelaxin
1.00
0.98
0.96
0.94
0.92
0.90
0.88
0.86
0.84
0.82
0 20 40 60 80
Study Day
100 120 140 160 180
Figure 1 Risk for All-Cause Mortality in
Pre-RELAX-AHF, RELAX-AHF, and Combined
The combined results represent stratified Kaplan-Meier estimates. p Values are
for log-rank tests in the individual studies and for the stratified log-rank test for
the combined studies. RELAX-AHF  Relaxin in Acute Heart Failure.WithFailuof Se
Acut
tinuou
n Incre
reath/m
mm Hg
vs. 0/
vs. 0/
mol/l
g/dl
bling
ex, whit
mic hea
re, time
rminal p
depend
o
(
T
w
c
t
s
v
a
S
d
P
n
a
a
5
9
a
(
t
c
A
a
A
l
n
o
l
r
R
s
c
R
o
a
d
s
a
200 Metra et al. JACC Vol. 61, No. 2, 2013
The RELAX-AHF Trial Januay 15, 2013:196–206day 2 (p  0.013) (Table 4) and no significant difference in
levels at day 5 after enrollment (p  0.18) (Fig. 3A) as well
as with fewer patients having substantial further increases in
hs-cTnT levels over baseline values at day 2 (Table 4).
Serelaxin-treated patients had a lower incidence of ad-
verse events classified as cardiac disorders through day 5
(15.8% with placebo, 12.3% with serelaxin; odds ratio: 0.75;
95% CI: 0.54 to 1.05).
WORSENING RENAL FUNCTION AND LIVER DAMAGE.
Worsening renal function, defined by a serum creatinine
increase of 0.3 mg/dl (27 mol/l) or a cystatin-C increase
f 0.3 mg/l (22 nmol/l) at day 2, occurred in 167 of 1,086
15.4%) and 212 of 1,081 (19.6%) patients, respectively.
hese measures of worsening renal function were associated
ith increased 180-day all-cause mortality (Table 3, Fig. 2B).
Association of Continuous Biomarker ChangesFrom Baseline With 180-Day Mortalityin the RELAX-AHF St dy
Table 2
Ass cia i n of Continuous Biomarker Changes
From Baseline With 180-Day Mortality
in the RELAX-AHF Study
Biomarker HR (95% CI)* p Value
Troponin (log2)
Day 2 1.66 (1.24–2.02) 0.0002
Day 5 1.22 (1.01–1.47) 0.039
Day 14 1.68 (1.40–2.01) 0.0001
Cystatin-C (log2)
Day 2 2.28 (1.02–5.10) 0.046
Day 5 1.77 (0.87–3.59) 0.11
Day 14 1.34 (0.64–2.81) 0.44
Creatinine (log2)
Day 2 1.64 (0.83–3.26) 0.15
Day 5 1.63 (0.88–3.00) 0.12
Day 14 1.12 (0.58–2.17) 0.74
NT-proBNP (log2)
Day 2 1.73 (1.42–2.12) 0.0001
Day 5 1.56 (1.30–1.88) 0.0001
Day 14 1.48 (1.20–1.82) 0.0002
*Adjusted for baseline value of biomarker.
NT-proBNP  N-terminal pro–brain natriuretic peptide. Other abbreviations as in Table 1.
Association of Substantial Biomarker Changes at 48 h FromRandomizati n With 180-Day Mortality in th Relaxin in Acute HeaTable 3 Association of Substant al Biomark r Changes at 48 hRandomization With 180-Day Mortality in the Relaxin i
Death T
Biomarker Change From Baseline to Day 2 No
Troponin (20% increase) 62/825
7.6 (6.0–9.6)
Creatinine (27 mol/l [0.3 mg/dl] increase) 75/919
8.2 (6.6–10.2)
Cystatin-C (22 nmol/l [0.3 mg/l] increase) 66/869
7.7 (6.1–9.7)
AST (20% increase) 73/906
8.1 (6.5–10.1)
ALT (20% increase) 79/970
8.2 (6.6–10.1)
NT-proBNP (30% decrease) 53/395
13.5 (10.5–17.4)Values are n/N with Kaplan-Meier percentages and 95% CIs.
ALT  alanine transaminase; AST  aspartate transaminase. Other abbreviations as in Tables 1 and 2Patients assigned to serelaxin had similar values of serum
reatinine and plasma cystatin-C at baseline, compared with
hose on placebo (Table 4). Serelaxin was associated with
ignificantly lower serum creatinine and plasma cystatin-C
alues in the first 5 days after enrollment (Table 4, Figs. 3B
nd 4A) and, in the case of cystatin-C, also at day 14 (Fig. 3B).
erelaxin administration was associated with a lower inci-
ence of worsening renal function at day 2 (Table 4).
atients on serelaxin also had lower levels of blood urea
itrogen and of uric acid at each day from day 1 to day 5
fter enrollment (Figs. 4B and 4C). The incidence of
dverse events classified as renal and urinary disorders was
.6% on placebo and 4.6% on serelaxin (odds ratio: 0.81;
5% CI: 0.47 to 1.37).
Increases of20% at day 2 in serum transaminases (AST
nd ALT) occurred in 99 of 1,005 (9.9%) and 99 of 1,069
9.3%) patients, respectively. These changes in serum
ransaminases were associated with increased 180-day all-
ause mortality (Table 3, Figs. 2C and 2D).
Serelaxin-treated patients had larger mean decreases in
ST at days 1 and 2 and in ALT at days 2 and 3 (Figs. 4D
nd 4E), and lower proportions of patients had AST and
LT increases of20% at day 2 (Table 4). Plasma bilirubin
evels were not different between serelaxin and placebo (data
ot shown). Adverse events classified as hepatobiliary dis-
rders through day 5 occurred less frequently in the sere-
axin group (1.8% with placebo, 0.2% with serelaxin; odds
atio: 0.10; 95% CI: 0.01 to 0.77).
eduction of congestion on serelaxin. The effects of
erelaxin on symptoms and signs of heart failure related to
ongestion during the first days after randomization in
ELAX-AHF have been described elsewhere (21). Patients
n placebo received higher doses of intravenous diuretic
gents over the first 5 days of the study. This difference was
riven mostly by differences at days 3, 4, and 5, with no
ignificant difference in doses of diuretic agents at days 1
nd 2 of the study (p  0.14 and p  0.10, respectively).
ilure Study
ute Heart Failure Study
Day 180
Yes HR (95% CI) p Value
30/231 1.80 (1.16–2.777) 0.0076
13.1 (9.3–18.2)
23/167 1.76 (1.11–2.82) 0.016
13.8 (9.4–20.0)
32/212 2.10 (1.38–3.20) 0.0004
15.2 (11.0–20.7)
13/99 1.66 (0.92–3.00) 0.099
13.4 (8.0–22.0)
15/99 1.96 (1.13–3.40) 0.015
15.3 (9.5–24.1)
45/686 0.47 (0.31–0.69) 0.0001
6.6 (5.0–8.8)rt FaFrom
n Ac
hrough.
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Januay 15, 2013:196–206 The RELAX-AHF TrialBaseline Values and Changes From Baseline in Biomarkers Related to Organ Damagein the RELAX-AHF StudyTable 4 Ba eline Values and Chang s From Baselin in Biomarkers Related to Organ Damagein the RELAX-AHF Study
Variable
Placebo
(n  580)
Serelaxin
(n  581) Treatment Effect (95% CI) p Value
Cardiac damage
hs-cTnT (g/l)
Baseline geometric mean 0.036 0.034
Below LLOQ (0.013 g/l) at baseline 34/541 (6.3%) 40/533 (7.5%)
Day 2 geometric mean 0.037 0.033
Below LLOQ at day 2 32/534 (6.0%) 37/523 (7.1%)
Relative change to day 2 (geometric mean change) 1.035 0.966 0.933 (0.883 to 0·985)* 0.013
20% increase at day 2 145/534 (27.2%) 86/522 (16.5%) 0.53 (0.39 to 0.71)† 0.0001
Worsening renal function
Serum creatinine (mol/l)§
Baseline mean 117 117
Day 2 mean 123 113
Mean change to day 2 6.2 3.4 9·5 (12.4 to6.6)‡ 0.001
0.3 mg/l (27 nmol/L) increase from baseline to day 2 108/545 (19.8%) 59/541 (10.9%) 0.50 (0.35 to 0.70)† 0.0001
Cystatin C (nmol/l)
Baseline geometric mean 109 109
Day 2 geometric mean 118 112
Relative change to day 2 (geometric mean change) 1.080 1.027 0.950 (0.931 to 0.970)* 0.001
0.3 mg/l (22 nmol/l) increase from baseline to day 2 126/542 (23.2%) 86/539 (16.0%) 0.63 (0.46 to 0.85)† 0.0027
BUN (mmol/l)¶
Baseline 9.8 9.7
Day 2 10.7 9.9
Change at day 2 (mmol/l) 0.8 0.2 0.62 (0.96 to0.28)‡ 0.001
Uric acid (mol/l)#
Baseline 475 476
Day 2 500 466
Change at day 2 (mol/l) 24.7 8.5 33 (42 to24)‡ 0.001
Liver function
ALT (U/l)
Baseline 28.4 31.1
Day 2 25.5 24.6
Change at day 2 (mg/dl) 2.3 6.4 4.16 (6.62 to1·70)‡ 0.001
20% increase at day 2 61/537 (11.4%) 38/532 (7.1%) 0.60 (0.39 to 0.92)† 0.018
AST (U/l)
Baseline 30.4 32.2
Day 2 27.5 24.5
Change at day 2 (mg/dl) 2.2 7.6 5·33 (9·04 to1·62)‡ 0.005
20% increase at day 2 64/502 (12.7%) 35/503 (7.0%) 0.51 (0.33 to 0.79)† 0.0024
Albumin (g/l)
Baseline 40.0 40.5
Day 2 38.5 39.1
Change at day 2 (mg/dl) 1.4 1.3 0.15 (0.23 to 0.53)‡ 0.45
Decongestion
NT-proBNP (ng/l)
Baseline geometric mean 5,003.50 5,125.46
Above ULOQ (35,000 ng/l) at baseline 6/551 (1.1%) 6/550 (1.1%)
Day 2 geometric mean 3,037.50 2,544.23
Above ULOQ at day 2 7/544 (1.3%) 1/538 (0.2%)
Relative change to day 2 (geometric mean change) 0.607 0.492 0.812 (0.753 to 0.876)* 0.001
30% decrease from baseline at day 2 315/543 (58.0%) 371/538 (69.0%) 1.61 (1.25 to 2.06)† 0.0002
*Ratio of geometric mean changes from repeated-measures analysis of covariance. †Odds ratio. ‡Mean difference. §Divide by 88.4 to convert from micromoles per liter to milligrams per deciliter. Divide
by 74.9 to convert from nanomoles per liter to milligrams per liter. No values were beyond the limits of quantitation at either baseline or day 2. ¶Multiply by 2.808 to convert from millimoles per liter to
milligrams per deciliter. #Multiply by 0.168 to convert from micromoles per liter to milligrams per deciliter.
BUN  blood urea nitrogen; hs-cTnT  high-sensitivity cardiac troponin T; LLOQ  lower limit of quantification; ULOQ  upper limit of quantification. Other abbreviations as in Tables 1 to 3.
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The RELAX-AHF Trial Januay 15, 2013:196–206They also showed significantly greater early reductions in
signs and symptoms of congestion (e.g., edema, rales,
orthopnea, jugular venous pressure, and dyspnea on exer-
tion) compared with patients on placebo.
NT-PROBNP LEVELS. Higher NT-proBNP levels were as-
ociated with increased 180-day all-cause mortality (Table 2),
nd their reduction during the first 2 days after enrollment
redicted better prognosis (Tables 3 and 4, Fig. 2E).
Patients assigned to serelaxin had similar baseline values
f plasma NT-proBNP compared with those on placebo
Table 4). Serelaxin was associated with significantly lower
T-proBNP levels at day 2 (Table 4, Fig. 3C), nonsignifi-
antly different levels at day 5, and no difference thereafter
Fig. 3C). Serelaxin administration was also associated with
greater proportion of patients having 30% decreases in
T-proBNP from baseline to day 2 compared with placebo
Table 4).
WORSENING HEART FAILURE. The 103 of 1,161 patients
(8.9%) who developed worsening heart failure by day 5 had
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Figure 2 Risk for Death by Early Changes in Markers of Organ
All-cause death through day 180 in Relaxin in Acute Heart Failure study patien
lute change in cystatin-C from baseline to day 2 (B), percentage increases in s
(D) from baseline to day 2, decrease in N-terminal pro–brain natriuretic peptid
day 5 (F).higher 180-day all-cause mortality (Fig. 2F). The risk fordeveloping worsening heart failure through day 5 was lower
in the serelaxin-treated patients (12.2% with placebo, 6.7%
with serelaxin; HR: 0.53; 95% CI: 0.36 to 0.79; p 
0.0016).
Discussion
Hospitalizations for AHF are associated with high mortality.
No major improvement in the early treatment of patients with
AHF, and hence in their prognosis, has occurred in more than
20 years (3,4,32). In the RELAX-AHF study, serelaxin
administration was associated with reduction in dyspnea but
had no effect on the composite secondary endpoint, including
60-day readmission and death, because of the lack of an effect
on readmissions. Serelaxin administration was associated with
improvements in measures of congestion and with a reduced
duration of the initial hospital stay. In the RELAX-AHF trial,
consistent with the Pre-RELAX-AHF phase II study (19),
the early administration of intravenous serelaxin was associated
with a combined 38% decrease in 180-day all-cause mortality
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Januay 15, 2013:196–206 The RELAX-AHF Trialserelaxin versus placebo starting to separate at 5 days after
enrollment in both studies. In the present study, we report that
serelaxin had favorable effects on the short-term changes in
multiple laboratory markers of cardiac, renal, and liver damage
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Figure 3 Biomarker Changes From Baseline
in the Placebo and Serelaxin Groups
Changes from baseline to each study day in the Relaxin in Acute Heart Failure
study in high-sensitivity (hs) troponin T (A), cystatin-C (B), and N-terminal pro–
brain natriuretic peptide (NT-proBNP) (C). *p  0.05, **p  0.005, and
***p  0.001 by repeated-measures analysis of variance with adjustment for
baseline value.known to be associated with long-term mortality in AHF. wThe role of ongoing myocardial injury in heart failure has
been established with the advent of sensitive assays for
myocardial necrosis (24,33). Multiple studies have demon-
strated a strong association between elevated troponin levels
in patients with heart failure and poor clinical outcomes. An
increase in troponin during the hospital stay is more specific
for myocardial damage associated with the acute episode
and, accordingly, has been shown to have an independent
relation with outcomes (23,34,35). It may therefore be
hypothesized that preventing myocardial damage, as evi-
denced by acute increases in troponin, might favorably
influence survival. Our study confirms that a rise in hs-
cTnT level during the hospital stay, assessed either as a
continuous measure or as a 20% increment, a cutoff chosen
on the basis of current recommendations (23), is associated
with increased 180-day all-cause mortality. Serelaxin ad-
ministration was associated with reductions at day 2 from
randomization, but not thereafter, in both overall levels of
hs-cTnT and the proportion of patients who had 20%
ncreases, providing a potential mechanism for the improved
urvival of serelaxin-treated patients.
The relationship between worsening renal function and
oor outcomes in patients with heart failure has been
stablished (25,36), although some uncertainty about the
mportance of transient worsening renal function persists
9,37). In the RELAX-AHF trial, creatinine levels at
aseline and worsening renal function, as measured by
ncreases in creatinine or cystatin-C, were associated with
ncreased 180-day all-cause mortality. Serelaxin administra-
ion was associated with lower levels of markers of renal
ysfunction as well as a reduced incidence of worsening
enal function, consistent with the hypothesis that the
revention of renal dysfunction during AHF hospitalization
avorably influences outcomes (3,9). Although some of this
ffect may be related to the use of greater doses of intrave-
ous loop diuretic agents in the placebo-treated arm, most
f the effect of serelaxin on renal function occurred early,
uring the first 2 days after randomization, when the
ifference in total doses of loop diuretic agents between
he 2 groups was nonsignificant (21). It is also possible that
he reduced need for loop diuretic agents in the serelaxin
rm, compared with the placebo arm, is the result, rather
han the cause, of improved kidney function. Patients
reated with serelaxin had on average larger decreases in
lood pressure, and hence the effect of serelaxin to reduce
arkers of renal impairment cannot be attributed to a lesser
lood pressure decrease (21).
The role of liver damage in AHF and its relation to
urvival is incompletely studied (10,11,38). In AHF, either
epatic congestion or direct liver injury through the activa-
ion of inflammatory cascades, oxidative stress, or other
echanisms could result in hepatic damage. Serelaxin ad-
inistration was associated with reduced levels of transami-
ases and with a trend toward higher levels of albumin, after
andomization, and both these changes have been associated
ith better survival in AHF (10,11,30). Plasma levels of uric
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The RELAX-AHF Trial Januay 15, 2013:196–206acid have also been related with mortality in heart failure
(39), and serelaxin administration reduced them in
RELAX-AHF.
Lack of, or slower, resolution of congestion during the
first days of admission for AHF has been associated with
more adverse outcomes (3,8,14). In its most extreme form,
lack of decongestion manifests as worsening heart failure,
and this event is associated with a 2-fold to 6-fold increase
in mortality (12–14,30). Persistently elevated natriuretic
peptide concentrations during the hospital stay have also
been associated with a poor prognosis, independent of
clinical signs (27,28). In the RELAX-AHF study, both
worsening heart failure during the hospital stay and a lack of
decrease in NT-proBNP levels during the hospital stay were
associated with increased 180-day all-cause mortality, con-
sistent with the hypothesis that persistent congestion may
worsen patients’ prognoses. Serelaxin administration signif-
icantly diminished signs and symptoms of congestion and
reduced NT-proBNP levels at 2 days after randomization,
but not thereafter, as well as the rate of worsening heart
20
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Figure 4 Early Changes From Baseline in Laboratory Values
Change from baseline in the Relaxin in Acute Heart Failure study in creatinine (A),
tate transaminase (AST) (E), and albumin (F). Changes are shown in Système Inte
0.05, **p  0.005, and ***p  0.001 by 2-sided, 2-sample t test for serelaxinfailure.Thus, this post-hoc analysis shows that serelaxin is associ-
ated with significant reductions in markers of end-organ
damage (cardiac, renal, and hepatic) and better relief from
congestion. All of these changes have been associated with
lower 180-day all-cause mortality in the present analysis as well
as in previous studies (3,10,24,25,27,28,33,36). These findings
suggest that organ damage and persistent congestion during
the first days of admission are important mechanisms of the
high mortality of patients with AHF and might be impor-
tant treatment targets in AHF. Other mechanisms were
likely present. Although treatment at days 5 and 14 was
similar between the patients assigned to serelaxin or placebo
(21), the administration of lower doses of diuretic agents
and the lesser use of inotropes in the patients randomized to
serelaxin may have contributed to their lower 180-day
mortality (3). Last, mechanisms such as increased aortic
impedance and afterload mismatch, inflammatory activa-
tion, and oxidative stress are likely related to the poor
prognosis of the patients hospitalized for AHF and are
potential targets of serelaxin (16–18). However, they are
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Januay 15, 2013:196–206 The RELAX-AHF TrialPatients were enrolled in both the RELAX-AHF and
Pre-RELAX-AHF studies early (the median time from
presentation was about 6 h) and were required to have
systolic blood pressures 125 mm Hg and elevated levels of
natriuretic peptides at the time of screening. Therefore, the
results of this study pertain to a subgroup of patients with
AHF and cannot be extrapolated to other AHF subgroups,
especially patients who present with low blood pressures.
However, the patients included in the RELAX-AHF pro-
gram may represent many patients with AHF, as demon-
strated in the Acute Decompensated Heart Failure National
Registry, in which 50% of the 186,805 patients enrolled had
blood pressures 140 mm Hg at presentation (3). Impor-
tantly, the benefit of serelaxin administration given the
potential improvement of dyspnea, length of stay, worsen-
ing heart failure, end-organ damage, and mortality should
be balanced against the lack of effect on readmissions shown
in this study.
Conclusions
Our results suggest that serelaxin reduced cardiac, renal, and
liver damage and persistent congestion during the first few
days after admission, and these beneficial effects may be
associated with increased survival. The post hoc exploratory
nature of our findings regarding the association between
early biomarkers changes and 180-day mortality suggests
that our study may be considered hypotheses generating and
that further studies may be required to further explore the
effects of serelaxin.
Reprint requests and correspondence: Dr. Marco Metra, Cardi-
ology, c/o Spedali Civili, Piazza Spedali Civili 1, 25123 Brescia,
Italy. E-mail: metramarco@libero.it.
REFERENCES
1. Fonarow GC, Abraham WT, Albert NM, et al. Influence of a
performance-improvement initiative on quality of care for patients
hospitalized with heart failure: results of the Organized Program to
Initiate Lifesaving Treatment in Hospitalized Patients With Heart
Failure (OPTIMIZE-HF). Arch Intern Med 2007;167:1493–502.
2. Solomon SD, Dobson J, Pocock S, et al. Influence of nonfatal
hospitalization for heart failure on subsequent mortality in patients
with chronic heart failure. Circulation 2007;116:1482–7.
3. Gheorghiade M, Pang PS. Acute heart failure syndromes. J Am Coll
Cardiol 2009;53:557–73.
4. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for
the diagnosis and treatment of acute and chronic heart failure 2012:
the Task Force for the Diagnosis and Treatment of Acute and Chronic
Heart Failure 2012 of the European Society of Cardiology. Developed
in collaboration with the Heart Failure Association (HFA) of the
ESC. Eur Heart J 2012;33:1787–847.
5. Laribi S, Aouba A, Nikolaou M, et al. Trends in death attributed to
heart failure over the past two decades in Europe. Eur J Heart Fail
2012;14:234–9.
6. Stevenson LW. Are hemodynamic goals viable in tailoring heart
failure therapy? Hemodynamic goals are relevant. Circulation 2006;
113:1020–7.
7. Cotter G, Metra M, Milo-Cotter O, Dittrich HC, Gheorghiade M.
Fluid overload in acute heart failure—re-distribution and other mech-
anisms beyond fluid accumulation. Eur J Heart Fail 2008;10:165–9.8. Gheorghiade M, Follath F, Ponikowski P, et al. Assessing and grading
congestion in acute heart failure: a scientific statement from the acute
heart failure committee of the Heart Failure Association of the
European Society of Cardiology and endorsed by the European
Society of Intensive Care Medicine. Eur J Heart Fail 2010;12:423–33.
9. Metra M, Cotter G, Gheorghiade M, Dei Cas L, Voors AA. The role
of the kidney in heart failure. Eur Heart J 2012;33:2135–42.
10. Ambrosy AP, Vaduganathan M, Huffman MD, et al. Clinical course
and predictive value of liver function tests in patients hospitalized for
worsening heart failure with reduced ejection fraction: an analysis of
the EVEREST trial. Eur J Heart Fail 2012;14:302–11.
11. van Deursen VM, Damman K, Hillege HL, van Beek AP, van Veldhu-
isen DJ, Voors AA. Abnormal liver function in relation to hemodynamic
profile in heart failure patients. J Card Fail 2010;16:84–90.
12. Torre-Amione G, Milo-Cotter O, Kaluski E, et al. Early worsen-
ing heart failure in patients admitted for acute heart failure: time
course, hemodynamic predictors, and outcome. J Card Fail 2009;
15:639 – 44.
13. Metra M, Teerlink JR, Felker GM, et al. Dyspnoea and worsening
heart failure in patients with acute heart failure: results from the
Pre-RELAX-AHF study. Eur J Heart Fail 2010;12:1130–9.
14. Metra M, O’Connor CM, Davison BA, et al. Early dyspnoea relief in
acute heart failure: prevalence, association with mortality, and effect of
rolofylline in the PROTECT study. Eur Heart J 2011;32:1519–34.
15. Allen LA, Hernandez AF, O’Connor CM, Felker GM. End points
for clinical trials in acute heart failure syndromes. J Am Coll Cardiol
2009;53:2248–58.
16. Teichman SL, Unemori E, Teerlink JR, Cotter G, Metra M. Relaxin:
review of biology and potential role in treating heart failure. Curr
Heart Fail Rep 2010;7:75–82.
17. Du XJ, Bathgate RA, Samuel CS, Dart AM, Summers RJ. Cardio-
vascular effects of relaxin: from basic science to clinical therapy. Nat
Rev Cardiol 2010;7:48–58.
18. Conrad KP, Shroff SG. Effects of relaxin on arterial dilation, remodeling,
and mechanical properties. Curr Hypertens Rep 2011;13:409–20.
19. Teerlink JR, Metra M, Felker GM, et al. Relaxin for the treatment of
patients with acute heart failure (Pre-RELAX-AHF): a multicentre,
randomised, placebo-controlled, parallel-group, dose-finding phase
IIb study. Lancet 2009;373:1429–39.
20. Ponikowski P, Metra M, Teerlink JR, et al. Design of the Relaxin in
Acute Heart Failure study. Am Heart J 2012;163:149–55.
21. Teerlink JR, Cotter G, Davison BA, et al., for the RELAXin in Acute
Heart Failure (RELAX-AHF) Investigators Serelaxin, recombinant
human relaxin-2, for the treatment of acute heart failure (RELAX-
AHF): a randomised, placebo-controlled trial. Lancet 2012 Nov 6
[E-pub ahead of print].
22. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of
myocardial infarction. Eur Heart J 2012;33:2551–67.
23. Thygesen K, Mair J, Giannitsis E, et al. How to use high-sensitivity
cardiac troponins in acute cardiac care. Eur Heart J 2012;33:2252–7.
24. Januzzi JL Jr., Filippatos G, Nieminen M, Gheorghiade M. Troponin
elevation in patients with heart failure: on behalf of the third Universal
Definition of Myocardial Infarction Global Task Force: Heart Failure
Section. Eur Heart J 2012;33:2265–71.
25. Gottlieb SS, Abraham W, Butler J, et al. The prognostic importance
of different definitions of worsening renal function in congestive heart
failure. J Card Fail 2002;8:136–41.
26. Lassus J, Harjola VP, Sund R, et al. Prognostic value of cystatin C in
acute heart failure in relation to other markers of renal function and
NT-proBNP. Eur Heart J 2007;28:1841–7.
27. Bettencourt P, Azevedo A, Pimenta J, Frioes F, Ferreira S, Ferreira A.
N-terminal-pro-brain natriuretic peptide predicts outcome after hospital
discharge in heart failure patients. Circulation 2004;110:2168–74.
28. Maisel A, Mueller C, Adams K Jr., et al. State of the art: using
natriuretic peptide levels in clinical practice. Eur J Heart Fail 2008;
10:824–39.
29. Cotter G, Metra M, Weatherley BD, et al. Physician-determined
worsening heart failure: a novel definition for early worsening heart
failure in patients hospitalized for acute heart failure—association with
signs and symptoms, hospitalization duration, and 60-day outcomes.
Cardiology 2010;115:29–36.
30. O’Connor CM, Mentz RJ, Cotter G, et al. The PROTECT
in-hospital risk model: 7-day outcome in patients hospitalized with
33
3
3
3
3
3
3
3
206 Metra et al. JACC Vol. 61, No. 2, 2013
The RELAX-AHF Trial Januay 15, 2013:196–206acute heart failure and renal dysfunction. Eur J Heart Fail
2012;14:605–12.
1. Laupacis A, Sackett DL, Roberts RS. An assessment of clinically
useful measures of the consequences of treatment. N Engl J Med
1988;318:1728–33.
2. Fang J, Mensah GA, Croft JB, Keenan NL. Heart failure-related
hospitalization in the U.S., 1979 to 2004. J Am Coll Cardiol
2008;52:428–34.
3. Kociol RD, Pang PS, Gheorghiade M, Fonarow GC, O’Connor CM,
Felker GM. Troponin elevation in heart failure prevalence, mecha-
nisms, and clinical implications. J Am Coll Cardiol 2010;56:1071–8.
4. Metra M, Bettari L, Pagani F, et al. Troponin T levels in patients with
acute heart failure: clinical and prognostic significance of their detec-
tion and release during hospitalisation. Clin Res Cardiol 2012;101:
663–72.
5. O’Connor CM, Fiuzat M, Lombardi C, et al. Impact of serial troponin
release on outcomes in patients with acute heart failure: analysis from the
PROTECT pilot study. Circ Heart Fail 2011;4:724–32.6. Damman K, Navis G, Voors AA, et al. Worsening renal function and
prognosis in heart failure: systematic review and meta-analysis. J Card
Fail 2007;13:599–608.
7. Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients
with acute decompensated heart failure. N Engl J Med 2011;364:
797– 805.
8. Filippatos GS, Desai RV, Ahmed MI, et al. Hypoalbuminaemia
and incident heart failure in older adults. Eur J Heart Fail
2011;13:1078 – 86.
9. Filippatos GS, Ahmed MI, Gladden JD, et al. Hyperuricaemia, chronic
kidney disease, and outcomes in heart failure: potential mechanistic
insights from epidemiological data. Eur Heart J 2011;32:712–20.
Key Words: congestion y heart failure y organ protection y RELAX-
AHF y serelaxin.
APPENDIXFor a list of the Study Personnel, please see the online version of this article.
